High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Background The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH.Methods Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6.Results The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228).Conclusions This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CRP is predictive of NASH in patients with NAFLD and is related to the presence and severity of liver fibrosis [133].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [133]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Koenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,964
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000080897.52664.94 · Cited by 1,506
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,296
Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
The natural history of nonalcoholic fatty liver: A follow-up study
Teli, M. R., James, O. F. W., Burt, A. D., Bennett, M. K., & Day, C. P. (1995) · Hepatology · doi:10.1002/hep.1840220616 · Cited by 925
Nonalcoholic Steatohepatitis: Definition and Pathology
Brunt, E. M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-12925 · Cited by 911
Non‐alcoholic fatty liver disease
ANGULO, P., & LINDOR, K. D. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.17.s1.10.x · Cited by 835
Abdominal Fat: Standardized Technique for Measurement at CT
Yoshizumi, T., Nakamura, T., Yamane, M., Waliul Islam, A. H. M., Menju, M., Yamasaki, K., Arai, T., Kotani, K., Funahashi, T., Yamashita, S., et al. (1999) · Radiology · doi:10.1148/radiology.211.1.r99ap15283 · Cited by 829
The Metabolic Syndrome as Predictor of Type 2 Diabetes
Lorenzo, C., Okoloise, M., Williams, K., Stern, M. P., & Haffner, S. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3153 · Cited by 803
Ridker, P. M., Rifai, N., & Clearfield, M. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00460-3 · Cited by 760
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691
Rutter, M. K., Meigs, J. B., Sullivan, L. M., D’Agostino, R. B., & Wilson, P. W. F. (2004) · Circulation · doi:10.1161/01.cir.0000136581.59584.0e · Cited by 664
Haukeland, J. W., Damås, J. K., Konopski, Z., Løberg, E. M., Haaland, T., Goverud, I., Torjesen, P. A., Birkeland, K., Bjøro, K., & Aukrust, P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.02.011 · Cited by 603
Hak, A. E., Stehouwer, C. D. A., Bots, M. L., Polderman, K. H., Schalkwijk, C. G., Westendorp, I. C. D., Hofman, A., & Witteman, J. C. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.8.1986 · Cited by 525
Alcohollike liver disease in nonalcoholics
Diehl, A. M., Goodman, Z., & Ishak, K. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90183-7 · Cited by 483
Long–Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C
Hui, J. M., Kench, J. G., Chitturi, S., Sud, A., Farrell, G. C., Byth, K., Hall, P., Khan, M., & George, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50320 · Cited by 437
Nonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogenic Cirrhosis
Clark, J. M., & Diehl, A. M. (2003) · JAMA · doi:10.1001/jama.289.22.3000 · Cited by 428
Prevalence and risk factors of non‐alcoholic fatty liver disease among Korean adults
PARK, S. H., JEON, W. K., KIM, S. H., KIM, H. J., PARK, D. I., CHO, Y. K., SUNG, I. K., SOHN, C. I., KEUM, D. K., & KIM, B. I. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.04086.x · Cited by 422
Liver Markers and Development of the Metabolic Syndrome
Hanley, A. J. G., Williams, K., Festa, A., Wagenknecht, L. E., D’Agostino, R. B., & Haffner, S. M. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3140 · Cited by 419
Baumann, H., & Gauldie, J. (1990) · PubMed · Cited by 326
Yamada, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.12.1183 · Cited by 235
Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region?
FARRELL, G. C. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02989.x · Cited by 235
Non‐alcoholic fatty liver disease: An overview
Mulhall, B. P., Ong, J. P., & Younossi, Z. M. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02881.x · Cited by 227
PARK, S. H., KIM, B. I., YUN, J. W., KIM, J. W., PARK, D. I., CHO, Y. K., SUNG, I. K., PARK, C. Y., SOHN, C. I., JEON, W. K., et al. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03362.x · Cited by 198
Liangpunsakul, S., & Chalasani, N. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200503000-00001 · Cited by 170
Evaluation of Blood Donors with Elevated Serum Alanine Aminotransferase Levels
Friedman, L. S., Dienstag, J. L., WATKINS, E., HINKLE, C. A., SPIERS, J. A., RIEDER, S. V., & HUGGINS, C. E. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-137 · Cited by 92
Katsuki, A., Sumida, Y., Urakawa, H., Gabazza, E. C., Murashima, S., Morioka, K., Kitagawa, N., Tanaka, T., Araki-Sasaki, R., Hori, Y., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020486 · Cited by 60
KURIOKA, S., MURAKAMI, Y., NISHIKI, M., SOHMIYA, M., KOSHIMURA, K., & KATO, Y. (2002) · Endocrine Journal · doi:10.1507/endocrj.49.459 · Cited by 35
Iwasaki, T., Nakajima, A., Yoneda, M., & Terauchi, Y. (2006) · Endocrine Journal · doi:10.1507/endocrj.k05-133 · Cited by 23
Self-citationTreatment of non‐alcoholic fatty liver disease
Sanyal, A. J. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.17.s3.32.x · Cited by 20
Ono, T., Shiga, N., Taneda, Y., et al. (1999) · Medical Entomology and Zoology · Cited by 19
HOMA 指数の適用範囲について-インスリン抵抗性と空腹時血糖値の関係からの考察-
小野, 利., 志賀, 伯., 種田, 嘉., & Umemura, S. (1999) · 糖尿病 · Cited by 18
Quantification of Llama Inflammatory Cytokine mRNAs by Real-Time RT-PCR
Odbileg, R., Konnai, S., Usui, T., Ohashi, K., & Onuma, M. (2005) · Journal of Veterinary Medical Science · doi:10.1292/jvms.67.195 · Cited by 17
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Research works printed but not linked: 4
- JM Hui, 2004, Hepatology, 40, 46
- T Ono, 1999, J Jpn Diabetes Soc, 42, 1005
- JM Hui, 2003, Hepatology, 38, 420
- H Baumann, 1990, Mol Biol Med, 7, 147
Cited by
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 944
Inflammatory mechanisms in the regulation of insulin resistance
Tilg, H., & Moschen, A. R. (2008) · Molecular Medicine · doi:10.2119/2007-00119.tilg · Cited by 779
“C-reactive protein (CRP), the most important human acute-phase protein, correlates with states of IR (96).”
BackgroundRehman, K., & Akash, M. S. H. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0303-y · Cited by 671
“CRP has been considred as one of the most important human acute phase protein that correlates with development of IR [58, 59].”
Background
Metadata
- Authors
- Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., Abe, Y., Kubota, K., Saito, S., Iwasaki, T., Terauchi, Y., Togo, S., Maeyama, S., & Nakajima, A.
- Affiliations
- Yokohama City University Hospital (JP)
- Yokohama City University (JP)
- Kitakashiwa Rehabilitation General Hospital (JP)
- ORCID
- Venue
- Journal of Gastroenterology
- Published
- 2007-07-25
- Volume
- 42
- Issue
- 7
- Pages
- 573-582
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2060798922
- Cited by
- 294
- References
- 50
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 9 · 2023: 16 · 2022: 17 · 2021: 19 · 2020: 15 · 2019: 10 · 2018: 10 · 2017: 17 · 2016: 18 · 2015: 14 · 2014: 14 · 2013: 21 · 2012: 14
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- high-sensitivity C-reactive protein, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, hepatic steatosis, liver fibrosis severity, interleukin-6, inflammatory markers, disease progression
- MeSH terms
- Adult, C-Reactive Protein, Fatty Liver, Female, Hepatitis, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Prospective Studies, RNA, Messenger, Severity of Illness Index, Biomarkers, Interleukin-6, Gene Expression, Logistic Models, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.